Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Pdcd4 suppresses tumor phenotype in JB6 cells by inhibiting AP-1 transactivation

Abstract

Transformation suppressor Pdcd4 is downregulated in transformed (Tx) mouse epidermal JB6 RT101 cells relative to transformation-resistant (P−) and susceptible (P+) variants. Whether Pdcd4 downregulation is necessary not only to induce transformation but also to maintain tumor phenotypes has not been determined previously. In the present study, overexpression of Pdcd4 cDNA in stably transfected RT101 cells resulted in 40% fewer anchorage-independent colonies that were smaller in size than the vector control colonies, indicating that elevated Pdcd4 expression is sufficient to suppress tumor phenotype. Transient transfection of Pdcd4 expression plasmid and 4 × AP-1 reporter gene showed that activation of AP-1-dependent transcription was inhibited by Pdcd4 expression in a concentration-dependent manner. In contrast, Pdcd4 did not inhibit serum response element-dependent transcription, indicating specificity. In a Gal4 fusion assay, Pdcd4 specifically inhibited activation of c-Jun and c-Fos activation domains, but did not inhibit activation of JunB, JunD, Fra-1, or Fra-2. Gel mobility shift assay demonstrated that c-Jun is the major component detected in the AP-1 complex in RT101 cells. Previous studies suggested that AP-1 activity is required for maintaining the transformed phenotype in RT101 cells. Thus, Pdcd4 suppresses tumor phenotype by inhibiting AP-1-dependent transcription, possibly through inhibiting c-Jun and c-Fos activation.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7

References

  • Angel P, Szabowski A and Schorpp-Kistner M . (2001). Oncogene, 20, 2413–2423.

  • Azzoni L, Zatsepina O, Abede B, Bennett IM, Kanakaraj P and Perussia B . (1998). J. Immunol., 161, 3493–3500.

  • Bernstein LR and Walker SE . (1999). Biochim. Biophys. Acta, 1489, 263–280.

  • Chauhan D, Auclair D, Robinson EK, Hideshima T, Li GL, Podar K, Gupta D, Richardson P, Schlossman RL, Krett N, Chen LB, Munshi NC and Anderson KC . (2002). Oncogene, 21, 1346–1358.

  • Chinenov Y and Kerppola TK . (2001). Oncogene, 20, 2438–2452.

  • Cmarik JL, Min H, Hegamyer G, Zhan S, Kulesz-Martin M, Yoshinaga H, Matsuhashi S and Colburn NH . (1999). Proc. Natl. Acad. Sci. USA, 96, 14037–14042.

  • Colburn NH . (1980). Carcinogen. Compr. Surv., 5, 33–56.

  • Colburn NH, Former BF, Nelson KA and Yuspa SH . (1979). Nature, 281, 589–591.

  • Colburn NH, Wendel EJ and Abruzzo G . (1981). Proc. Natl. Acad. Sci. USA, 78, 6912–6916.

  • Coussens LM, Fingleton B and Matrisian LM . (2002). Science, 295, 2387–2392.

  • Domann FE, Levy JP, Birrer MJ and Bowden GT . (1994). Cell Growth Differ., 5, 9–16.

  • Dong Z, Lavrovsky V and Colburn NH . (1995a). Carcinogenesis, 16, 749–756.

  • Dong Z, Watts RG, Sun Y, Zhan S-N and Colburn N . (1995b). Int. J. Oncol., 7, 359–364.

  • Holt JT, Gopal TV, Moulton AD and Nienhuis AW . (1986). Proc. Natl. Acad. Sci. USA, 83, 4794–4798.

  • Hsu TC, Nair R, Tulsian P, Camalier CE, Hegamyer GA, Young MR and Colburn NH . (2001). Cancer Res., 61, 4160–4168.

  • Hsu TC, Young MR, Cmarik J and Colburn NH . (2000). Free Radic. Biol. Med., 28, 1338–1348.

  • Kazumi S and Colburn NH . (2002). Oncogene, 21, 2181–2190.

  • Kovary K and Bravo R . (1991). Mol. Cell. Biol., 11, 4466–4472.

  • Li JJ, Cao Y, Young MR and Colburn NH . (2000). Mol. Carcinogen., 29, 159–169.

  • Li JJ, Rhim JS, Schlege R, Vousden KH and Colburn NH . (1998). Oncogene, 28, 2711–2721.

  • Liu Y, Ludes-Meyers J, Zhang Y, Munoz-Medellin D, Kim HT, Lu C, Ge G, Schiff R, Hilsenbeck SG, Osborne CK and Brown PH . (2002). Oncogene, 21, 7680–7689.

  • Nishikura K and Murray JM . (1987). Mol. Cell. Biol., 7, 639–649.

  • Onishi Y and Kizaki H . (1996). Biochem. Biophys. Res. Commun., 228, 7–13.

  • Ozanne BW, McGarry L, Spence HJ, Johnston I, Winnie J, Meagher L and Stapleton G . (2000). Eur. J. Cancer, 36, 1640–1648.

  • Pause A, Methot N, Svitkin Y, Merrick WC and Sonenberg N . (1994). EMBO J., 13, 1205–1215.

  • Rapp UR, Troppmair J, Beck T and Birrer MJ . (1994). Oncogene, 9, 3493–3498.

  • Rogers Jr GW, Komar AA and Merrick WC . (2002). Prog. Nucleic Acid Res. Mol. Biol., 72, 307–331.

  • Schreiber M, Kolbus A, Piu F, Szabowski A, Mohle-Steinlein U, Tian J, Karin M, Angel P and Wagner EF . (1999). Genes Dev., 13, 607–619.

  • Schutte J, Minna JD and Birrer MJ . (1989a). Proc. Natl. Acad. Sci. USA, 86, 2257–2261.

  • Schutte J, Viallet J, Nau M, Segal S, Fedorko J and Minna J . (1989b). Cell, 59, 987–997.

  • Shaulian E and Karin M . (2001). Oncogene, 20, 2390–2400.

  • Shaulian E and Karin M . (2002). Nat. Cell. Biol., 4, E131–E136.

  • Shibahara K, Asano M, Ishida Y, Aoki T, Koike T and Honjo T . (1995). Gene, 166, 297–301.

  • Smith LM, Wise SC, Hendricks DT, Sabichi AL, Bos T, Reddy P, Brown PH and Birrer MJ . (1999). Oncogene, 18, 6063–6070.

  • Suzuki T, Murakami M, Onai N, Fukuda E, Hashimoto Y, Sonobe MH, Kameda T, Ichinose M, Miki K and Iba H . (1994). J. Virol., 68, 3527–3535.

  • Svitkin YV, Pause A, Haghighat A, Pyronnet S, Witherell G, Belsham GJ and Sonenberg N . (2001). RNA, 7, 382–394.

  • Takahashi K, Heine UI, Junker JL, Colburn NH and Rice JM . (1986). Cancer Res., 46, 5923–5932.

  • Watts RG, Ben-Ari ET, Bernstein LR, Birrer MJ, Winterstein D, Wendel E and Colburn NH . (1995). Mol. Carcinogen., 13, 27–36.

  • Yang HS, Jansen AP, Komar AA, Zheng X, Merrick WC, Costes S, Lockett SJ, Sonenberg N and Colburn NH . (2003). Mol. Cell. Biol., 23, 26–37.

  • Yang HS, Jansen AP, Nair R, Shibahara K, Verma AK, Cmarik JL and Colburn NH . (2001). Oncogene, 20, 669–676.

  • Young MR, Nair R, Bucheimer N, Tulsian P, Brown N, Chapp C, Hsu TC and Colburn NH . (2002). Mol. Cell. Biol., 22, 587–598.

  • Zhang ZH and DuBois RN . (2001). Oncogene, 20, 4450–4456.

Download references

Acknowledgements

We thank the members of the Gene Regulation Section for helpful discussions.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Hsin-Sheng Yang.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yang, HS., Knies, J., Stark, C. et al. Pdcd4 suppresses tumor phenotype in JB6 cells by inhibiting AP-1 transactivation. Oncogene 22, 3712–3720 (2003). https://doi.org/10.1038/sj.onc.1206433

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1206433

Keywords

This article is cited by

Search

Quick links